
News|Articles|February 13, 2019
Tegsedi for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
Author(s)Drew Boxler
Advertisement
Tegsedi (inotersen, Akcea™ Therapeutics)
Indications: Adult Patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis.
Dosage: 284 mg adminstered by subcutaneous injection 1x weekly
Contraindications
- Platelet count less than 100 x 109/L (4, 5.1)
- History of acute glomerulonephritis caused by TEGSEDI
- Patients with a history of a hypersensitivity reaction to TEGSEDI
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Q&A: Why Community Pharmacies are Displeased with the MDPNP | NCPA 2025
2
FDA Releases Biosimilar Guidance Pushing to Streamline Development
3
COVID-19 Vaccination Benefits Patients With Systemic Lupus Erythematosus
4
General Awareness of PBM Practices Driving Optimism for Independent Pharmacies | NCPA 2025
5




















































































































































